# Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

> **NCT05278364** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 184 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Medullary Thyroid Cancer
- Solid Tumor

## Interventions

- **DRUG:** SY-5007

## Key facts

- **NCT ID:** NCT05278364
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-23
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-02-10
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278364, "Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05278364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*